Skip to main navigation
Skip to search
Skip to main content
Augusta University Research Profiles Home
Help & FAQ
Home
Profiles
Research units
Equipment
Grants
Scholarly Output
Datasets
Activities
Prizes
Search by expertise, name or affiliation
Targeted Therapies in Chronic Myeloid Leukemia
Elias Jabbour,
Jorge Cortes
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeted Therapies in Chronic Myeloid Leukemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Accelerated Phase
25%
Adenosine Triphosphate
25%
BCR-ABL Fusion Gene
25%
Busulfan
25%
Cell Proliferation
25%
Chronic Myeloid Leukemia
100%
Commercially Available
25%
Complete Cytogenetic Response
25%
Complete Molecular Response
25%
Dasatinib
25%
ENESTnd
25%
Frontline Management
50%
Frontline Treatment
25%
Hydroxyurea
25%
Imatinib
25%
Interferon-α (IFN-α)
25%
Major Molecular Response
25%
Nilotinib
25%
Progression Rate
25%
Second-generation Tyrosine Kinase Inhibitors
25%
Small Molecule Tyrosine Kinase Inhibitors
25%
Targeted Therapy
100%
Tyrosine Kinase Inhibitor
25%
Medicine and Dentistry
Adenosine Triphosphate
25%
BCR ABL Protein
25%
Busulfan
25%
Cell Proliferation
25%
Chronic Myelogenous Leukemia
100%
Dasatinib
25%
Hydroxyurea
25%
Imatinib
25%
Interferon Alfa
25%
Mental Capacity
25%
Nilotinib
25%
Targeted Therapy
100%
Tyrosine-Kinase Inhibitor
75%
Biochemistry, Genetics and Molecular Biology
Adenosine Triphosphate
25%
Busulfan
25%
Cell Proliferation
25%
Cytogenetics
25%
Dasatinib
25%
Hydroxycarbamide
25%
Imatinib
25%
interferon
25%
Interferon
25%
Mental Capacity
25%
Myeloid
100%
Nilotinib
25%
Small Molecule
25%
Tyrosine Kinase Inhibitor
75%
Nursing and Health Professions
Adenosine Triphosphate
25%
Alpha Interferon
25%
BCR ABL Protein
25%
Busulfan
25%
Chronic Myeloid Leukemia
100%
Dasatinib
25%
Hydroxyurea
25%
Imatinib
25%
Nilotinib
25%
Protein Tyrosine Kinase Inhibitor
75%
Pharmacology, Toxicology and Pharmaceutical Science
Adenosine Triphosphate
25%
Alpha Interferon
25%
BCR ABL Protein
25%
Busulfan
25%
Chronic Myeloid Leukemia
100%
Dasatinib
25%
Hydroxycarbamide
25%
Imatinib
25%
Nilotinib
25%
Protein Tyrosine Kinase Inhibitor
75%